Evidence map›Paper›PMID 39154152›Full record

ArticleAnnals of surgical oncology2024

Clinical and Pathologic Response to Neoadjuvant Immunotherapy in DNA Mismatch Repair Protein-Deficient Gastroesophageal Cancers.

Adrienne B Shannon, Rutika Mehta, Shaffer R Mok, Gregory Y Lauwers, Jobelle J A R Baldonado, Jacques Fontaine, Jose M Pimiento, Andrew J Sinnamon

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adrienne B ShannonDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. adriennebruceshannon@gmail.com.
Rutika MehtaDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Shaffer R MokDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Gregory Y LauwersDepartment of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Jobelle J A R BaldonadoDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Jacques FontaineDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Jose M PimientoDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Andrew J SinnamonDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMismatch repair deficient (dMMR) gastroesophageal cancers (GEC) are a distinct subgroup. Among patients with locally advanced disease, previous trial data suggest a good response to neoadjuvant immune checkpoint inhibitors (nICI). PATIENTS AND

methodsSince 2019, our institution has routinely performed MMR testing for new GEC cases. Patients diagnosed with GEC (2019-2024) were included in the study. Quantitative data are described as the median and interquartile range (IQR); qualitative data are described as quantities and percentages.

resultsA total of 24 patients with dMMR GEC were identified following implementation of routine immunohistochemical testing; 14 were potentially resectable with a median follow-up of 14 months (IQR 8-27). All patients underwent pre-treatment positron emission tomography (PET; median SUV 20.9). Among the 14 potentially resectable patients, 4 underwent immediate surgery, 10 were treated with nICI, and 5 underwent surgical resection to date. All regimens included PD-1 inhibitors, with 70% receiving pembrolizumab. Re-staging PET was performed in five patients; the median post-nICI SUV was 5.1 (range 4.7-6.3). All resected specimens had gross ulceration after nICI, but 60% (N = 3) had a pathologic complete response (pCR) following nICI; one patient had a near-complete response (nCR) and one patient had a partial response (pPR). Reduction in SUV was 75% and 82% in the pCR patients, 25% in the nCR patient, and 43% in the pPR patient.

conclusionsdMMR GECs are responsive to nICI in this limited experience, mirroring early clinical trial data. Given persistent metabolic activity and visible ulceration despite pCR, studies should continue to optimize tools for estimating post-nICI pCR in these patients.

Indexed as

DNA Mismatch RepairEsophageal NeoplasmsNeoadjuvant TherapyStomach NeoplasmsAgedFemaleFollow-Up StudiesHumansImmune Checkpoint InhibitorsImmunotherapyMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateImmune Checkpoint InhibitorsGastric cancerGastroesophageal cancerImmunotherapyMicrosatellite instabilityMismatch repair protein deficientNeoadjuvant treatment response

Identifiers

PMID39154152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.